{
    "2018-02-13": [
        [
            {
                "time": "2018-02-13",
                "original_text": "Health Care Sector Update for 02/13/2018: ABC,WBA,LLY,BDX,DARE",
                "features": {
                    "keywords": [
                        "Health Care",
                        "Sector Update",
                        "ABC",
                        "WBA",
                        "LLY",
                        "BDX",
                        "DARE"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-02-13",
                "original_text": "Health Care Sector Update for 02/13/2018: DARE,LLY,BDX",
                "features": {
                    "keywords": [
                        "Health Care",
                        "Sector Update",
                        "DARE",
                        "LLY",
                        "BDX"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-02-14",
                "original_text": "Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for February 14, 2018",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Ex-Dividend",
                        "LLY"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-02-13",
                "original_text": "Health Care Sector Update for 02/13/2018: JNJ, PFE, ABT, MRK, AMGN, ABC, GNC, LLY, DARE, HCM, CLLS, BDX",
                "features": {
                    "keywords": [
                        "Health Care",
                        "Sector Update",
                        "JNJ",
                        "PFE",
                        "ABT",
                        "MRK",
                        "AMGN",
                        "ABC",
                        "GNC",
                        "LLY",
                        "DARE",
                        "HCM",
                        "CLLS",
                        "BDX"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-02-13",
                "original_text": "Eli Lilly's Taltz meets primary endpoint in late-state trial for AS treatment",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Taltz",
                        "primary endpoint",
                        "trial",
                        "AS treatment"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-02-13",
                "original_text": "Lilly Announces Positive Top-Line Phase 3 Results for TaltzÂ® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Positive",
                        "Top-Line",
                        "Phase 3",
                        "Taltz",
                        "Ankylosing Spondylitis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-02-13",
                "original_text": "Eli Lilly: Taltz Phase 3 Study Meets Endpoints To Treat Ankylosing Spondylitis",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Taltz",
                        "Phase 3",
                        "Endpoints",
                        "Ankylosing Spondylitis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}